Total n (wt%) | Asthma attack | Asthma-related ED | ≥ 2 asthma symptoms | Work/school absenteeism | Asthma medication | Lung function | ||||
---|---|---|---|---|---|---|---|---|---|---|
≥ 1 reliever medication† | ≥ 2 controller medication | FEV1 < LLN | FEV1% predicted§ | FEV1/FVC < LLN | ||||||
< 40 yrs | ||||||||||
1 phenotype | 118 (56) | 85 (70) | 27 (20) | 59 (56) | 15 (21) | 55 (43) | 17 (11) | 10 (7) | 95.6 (90.2–102.1) | 26 (20) |
2 phenotypes | 97 (40) | 69 (75) | 26 (32) | 57 (73) | 12 (9) | 41 (40) | 8 (9) | 19 (23) | 91.8 (81.3–99.2) | 25 (29) |
3 phenotypes | 12 (4) | 10 (73) | 5 (40) | 8 (72) | 4 (25) | 9 (68) | 1 (4) | 3 (36) | 81.9 (75.3–84.6) | 4 (29) |
p value* | ||||||||||
1 versus 2 | 0.43 | 0.10 | 0.052 | 0.04 | 0.72 | 0.64 | 0.006 | 0.07 | 0.25 | |
2 versus 3 | 0.92 | 0.55 | 0.96 | 0.07 | 0.15 | 0.46 | 0.43 | 0.009 | 0.98 | |
1 versus 3 | 0.86 | 0.11 | 0.39 | 0.73 | 0.20 | 0.34 | 0.01 | < 0.001 | 0.48 | |
≥ 40 yrs | ||||||||||
1 phenotype | 153 (46) | 104 (65) | 35 (23) | 76 (62) | 20 (15) | 58 (33) | 26 (17) | 29 (20) | 91.2 (81.6–99.2) | 34 (26) |
2 phenotypes | 136 (41) | 92 (69) | 28 (21) | 70 (55) | 12 (9) | 60 (46) | 43 (36) | 31 (37) | 80.4 (70.0–91.7) | 27 (32) |
≥ 3 phenotypes | 41 (13) | 26 (72) | 4 (9) | 30 (70) | 8 (40) | 22 (60) | 16 (40) | 12 (46) | 74.0 (63.0–85.8) | 16 (53) |
p value* | ||||||||||
1 versus 2 | 0.56 | 0.82 | 0.38 | 0.41 | 0.12 | 0.02 | 0.01 | 0.007 | 0.46 | |
2 versus ≥ 3 | 0.80 | 0.27 | 0.30 | 0.002 | 0.24 | 0.67 | 0.47 | 0.22 | 0.09 | |
1 versus ≥ 3 | 0.50 | 0.21 | 0.54 | 0.03 | 0.053 | 0.02 | 0.01 | 0.006 | 0.02 |